CKD-aP in focus: A comprehensive guide from recognition to relief for local practice

Abstract

Introduction

Chronic kidney disease-associated pruritus (CKD-aP) affects up to 50% of dialysis patients and significantly impairs quality of life. Despite its prevalence and impact, CKD-aP remains under-recognized and undertreated in clinical practice.

Methods

A narrative review was conducted using PubMed, Scopus, and Google Scholar. Studies were selected based on clinical relevance, methodological rigor, and focus on validated patient-reported outcome measures (PROMs) and therapeutic trials, particularly involving gabapentinoids and κ-opioid receptor agonists. Key topics were reviewed jointly by nephrology and dermatology specialists, who collaborated to develop a synthesized management algorithm and treatment summary table through expert discussion.

Results

This interdisciplinary review provides an overview of CKD-aP pathophysiology (Figure 1) and outlines a diagnostic algorithm (Figure 2) incorporating symptom screening, exclusion of differential diagnoses, and PROM-based severity assessment. A stepwise treatment approach is presented (Figure 3), beginning with emollients, followed by gabapentinoids, and advancing to difelikefalin—the first FDA (United States), EMA (European Union) and HSA (Health Sciences Authority) of Singapore-approved treatment for moderate-to-severe CKD-aP. The review is designed as a user-friendly resource for clinicians and nurses, regardless of their specialty background.

Conclusion

CKD-aP is a complex and distressing condition requiring greater awareness and multidisciplinary care. While effective therapies like difelikefalin exist, their use is limited by cost and unfamiliarity. Future priorities should include improving access, comparing available treatments, exploring alternative drug delivery routes, and integrating quality-of-life assessments into routine care.

Keywords

nephrology dermatology ckd-ap itch hemodialysis

Introduction

Itch is a significant global health issue, affecting 39.8% of the global population regardless of the underlying cause.¹ Chronic kidney disease-associated pruritus (CKD-aP), previously known as uraemic pruritus, is a persistent and distressing symptom commonly experienced by patients with chronic kidney disease (CKD).^2–4 Unlike dermatological causes of itch, CKD-aP typically lacks visible dermatosis.^5–7 Approximately 20% of CKD patients experience this symptom, with prevalence up to nearly 50% in those undergoing dialysis.⁸

CKD-aP profoundly impacts patients’ quality of life (QoL), which is often related to mortality and life expectancy. The Standardized Outcomes in Nephrology (SONG) initiative identified itch as a critical symptom in haemodialysis care.⁹ CKD-related pruritus profoundly affects quality of life and healthcare utilization, leading to irritability, sleep disturbances, fatigue, anxiety, depression, and social withdrawal.¹⁰ Moreover, it has been associated with increased hospitalizations due to infections and cardiovascular complications. Higher mortality rates also are observed in the Dialysis Outcomes and Practice Patterns Study (DOPPS) population, which was believed to be due to insomnia.^11–13

Despite its burden, CKD-aP is underreported and under-treated, largely due to lack of awareness among patients, nurses, and physicians, as well as the effective, guideline-supported therapies.¹⁴ This review provides an easily accessible and practical guide for healthcare providers to improve recognition, assessment, and management of CKD-aP in real-world clinical settings, regardless of their prior experience in nephrology or dermatology.

Methods

This narrative review compiles current literature on chronic kidney disease-associated pruritus (CKD-aP), to synthesize a comprehensive update on its pathophysiology, diagnostic approaches, and management strategies. Data were derived from randomized controlled trials (e.g., KALM-1, KALM-2), systematic reviews, real-world observational studies, and evidence-based clinical guidelines from both nephrology and dermatology perspectives. Emphasis was placed on high-quality studies, including meta-analyses and large cohort investigations, particularly those evaluating systemic treatments such as gabapentinoids and κ-opioid receptor agonists.

Relevant literature was identified through a comprehensive search of major databases, including PubMed, Scopus, and Google Scholar, using search terms such as “CKD-associated pruritus,” “uremic pruritus,” “difelikefalin,” “gabapentin,” “itch in dialysis,” and “pruritus management.” Articles were selected based on clinical relevance, methodological method, and applicability to routine clinical practice.

Validated assessment tools and evidence-based algorithms—such as the Dermatology Life Quality Index (DLQI) and the Worst Itch Numeric Rating Scale (WI-NRS)—were reviewed to support clinical utility. Key topics were reviewed jointly by nephrology and dermatology specialists, to develop a management algorithm and treatment summary table through expert discussion.

The recommended diagnostic and management algorithm and treatment summary are detailed in Figures 2 and 3, and Table 1, respectively.

Table 1.

Summary of the authors’ recommended therapeutic agents for management of CKD-aP (Grade of recommendation/level of evidence is based on GRADE working group).

	GRADE	Itch intensity	Mechanism of action	Authors’ recommendation
1. Toxin removal
a. Optimisation of dialysis	1C	Mild	Increase clearance of uremic toxins which are pruritogens	We recommend to use the Kt/V targets associated with optimal clinical outcomes even though there is no specific target Kt/V has been established for managing pruritus.
b. Optimization of CKD-MBD parameters	2C	Mild	Reduction in PTH and Ca-PO4 product; mechanism remains unclear	We suggest to optimise MBD parameters associated with optimal clinical outcomes even though the optimal “goals” target for patients with pruritus are unknown. MBD parameters are not associated with pruritus in the highest quality observational data available (DOPPS)
2. Immune system dysregulation
a. Topical emollients	1B	Mild	Reduce xerosis – moisturizing and emollient therapy with high hydrating and covering properties	We recommend to use the topical emollients to reduce xerosis as initial step. Ensure patients apply at least 200 g/week of emollients.
b. Topical capsaicin	2B	Mild		Topical capsaicin can be considered as an adjunctive treatment to topical emollients as there is limited evidence of efficacy of capsaicin in CKD/ESRD patients.
c. Topical tacrolimus	2C	Mild	Prevents transcription of messenger RNA for various inflammatory cytokines (IL-2) in Th1 and Th2	Topical tacrolimus 0.1% ointment may be considered for limited areas with recalcitrant itch. It was used 3 times a week in the clinical trial; in real world practice, it is used twice daily. Patients should be warned of possibility of a transient burning sensation after application, which reduces with subsequent applications. Cost may be a limiting factor.
d. Antihistamines	2D	Mild	Block effects of histamine, reducing its contribution to itch	We do not recommend antihistamines as it is ineffective in CKD-aP and causes side effects such as drowsiness which predisposes to falls in elderly patients.
e. Ultraviolet B (UVB) phototherapy	2A	Resistant	UVB modulates Th 1 and 2 lymphocyte differentiation and decreases production of IL-2	We suggest UVB phototherapy in moderate-to-severe and resistant CKD-aP in patients who are able to stand within a confined space for several minutes 1-3 times weekly. It may cause side effects such as sunburn, tanning, dryness and a possible risk of skin cancer, particularly in immunosuppressed patients.
3. Abnormal nerve conduction
a. Gabapentinoids (gabapentin, pregabalin)	1A	Moderate to severe	Act on voltage-gated calcium channels to reduce the release of itch-related mediators and diminish nerve sensitization	We recommend to use gabapentinoids as one of the first line (off-label) treatments but with extra caution. Patients should be warned of adverse effects such as dizziness, somnolence, confusion, dry mouth, and an increased risk of suicidal thoughts, which need to be closely monitored.
b. Serotonin antagonists	2C	Moderate to severe	5-HT3, a potential pruritogen, receptor antagonist	An example is low dose mirtazapine if there is no other choice due to limited evidence. Warn patients of risk of drowsiness, dizziness and weight gain.
c. SSRI (selective serotonin reuptake inhibitors)	2C	Moderate to severe	Enhances the natural inhibitory pathyway for itch. Also, reduces circulating IL-6 and TNF-alpha	An example is sertraline if there is no other choice due to limited evidence. Warn patients of risk of dizziness and weight changes.
d. Acupuncture	2A	Resistant	Block spinal cord release of opiod-like substances	Acupuncture may be considered in resistant CKD-aP.
4. Endogenous opioid dysregulation
a. Difelikefalin	1A	Moderate to severe	Peripherally restricted, selective κ-opioid receptor (KOR) agonist	We recommend to use IV difelikefalin 0.5mcg/kg (dry body weight) 3x/week after haemodialysis as first line in moderate to severe CKD-aP. It is licensed for CKD-aP in US, UK, Japan, Singapore. uncommon side-effects include diarrhea, dizziness, nausea, somnolence, and falls.
b. Nalfurafine	1A	Moderate to severe	Selective KOR receptor agonist	Nalfurafine is presently only licensed for CKD-aP in Japan and Korea. Patients should be warned of risk of insomnia, which resolves rapidly upon discontinuing the therapy.
c. Naltrexone, naloxone	2A	Moderate to severe	Mu opiod receptor (MOR) antagonist	Consider naltrexone as alternative if there is no KOR receptor agonist. It is effective in a subset of patients and need to watch out for side effects such as sedation, gastrointestinal complications.
d. Nalbuphine	2A	Moderate to severe	Mixed opioid agonist and antagonist activity (centrally acting MOR partial antagonist and KOR agonist)	Consider nalbuphine as alternative if there is no KOR receptor agonist. There is evidence that nalbuphine is effective but need to watch out for serious side effect such as respiratory depression.

Abbreviation: Ca: calcium; CKD: chronic kidney disease; CKD-aP: chronic kidney disease associated pruritus; DOPPS: dialysis outcomes and practice patterns study; ESRD: end-stage renal disease; GRADE: grading of recommendations assessment, development and evaluation; HT3: 5-hydroxytryptamine type 3 receptor; IL-2: interleukin-2; Kt/V: clearance of urea times dialysis time (Kt) divided by the volume of urea distribution (V); MBD: mineral and bone disorder; PTH: parathyroid hormone; PO4: Phosphate; RNA: ribonucleic acid; Th1: T helper cells type 1; Th2: T helper cells type 2; TNF: tumor necrosis factor.

Results

Section 1: Pathophysiology of CKD-aP

The complex and multifactorial pathogenesis of CKD-aP is summarized in a simplified visual diagram, as illustrated in Figure 1.

Figure 1.

Pathophysiology of chronic kidney disease-associated pruritus (CKD-aP).

The accumulation of uraemic toxins is one of the earliest theories mentioned. Proposed pruritogenic toxins like aluminium, phosphorus, and vitamin A deposit in the skin, leading to local inflammation and pruritus. Hence inadequate dialysis clearance has been identified as the main contributor to pruritus intensity in haemodialysis (HD) patients, with poor removal of pruritogenic substances associated with increased itch severity.^15,16

Another possible causative factor is peripheral neuropathy – where the damaged small nerve fibers are activated out of proportion, impairing autonomic regulation. This may enhance pruritic stimuli through central and peripheral mechanisms.^17,18

Inflammatory dysregulation is another key factor. Elevated levels of IL-31, IL-4, and IL-13 activate pruritogenic pathways.^17,18 This overlap with other chronic skin disorders such as atopic dermatitis.¹⁹

Lastly, a recent and crucial discovery in the pathogenesis of CKD-aP involves dysfunction of the opioid receptor system, which has led to the development of targeted κ-opioid receptor agonists. Patients with CKD-aP exhibit an imbalance between mu-opioid receptors (MOR) and kappa-opioid receptors (KOR). KOR which has antipruritic effect are reduced, while MOR which is the antagonism of KOR are overstimulated.²⁰ These have founded the therapeutic rationale for selective KOR agonists such as difelikefalin and nalfurafine.^5,21

Section 2: Initial assessment (e.g., WI-NRS, SADS, DLQI etc.)

CKD-aP often goes undiagnosed due to lack of awareness and diagnostic guidelines. We propose a three-step, simplified diagnostic algorithm as shown in Figure 2.^22,23

(1) Screening can begin with a single, validated question: “Have you experienced itch recently?” This approach promotes early symptom recognition, as it is easily understood by patients and usable by healthcare personnel.^1,24 It encourages multidisciplinary involvement in symptom monitoring as it can be readily adopted not only by busy physicians in polyclinics, nephrologist in ward round and dialysis nurses in dialysis centre.

(2) Exclusion of other potential causes can be done by a thorough clinical history and physical examination. Conditions such as primary dermatological conditions (xerosis, atopic dermatitis), or secondary causes such as hepatic disorders, and neuropathic or psychogenic pruritus must be ruled out. Referral to dermatology is recommended when the diagnosis remains uncertain or treatment options need to be sought via multidisciplinary discussion. Additionally, laboratory investigations such as Kt/V or the urea reduction ratio should be performed to assess dialysis adequacy, along with serum phosphate, calcium, and parathyroid hormone levels, all of which may contribute to pruritus severity.¹⁵

(3) Severity assessment of CKD-aP should incorporate validated patient-reported outcome measures (PROMs) to quantify both itch intensity and its impact on quality of life (QoL).^17,25 Their main clinical utility is to facilitate the monitoring and treatment response.²⁶

(A) Unidimensional tools, such as Worst Itch Numerical Rating Scale (WI-NRS), Visual Analogue Scale (VAS), and Verbal Rating Scale (VRS), are commonly used in clinical practice due to their ease of administration and reliability^.27 Among these, WI-NRS is particularly recommended, as it has been validated in major CKD-aP clinical trials such as KALM-1 and KALM-2.²⁸ This single-question assessment has shown strong correlation with health-related QoL domains and is feasible for routine use. It helps clinicians in individualizing the treatment decision, but with limitations such as subjectivity and reduced applicability in cognitively impaired individuals.²⁹

(B) Multidimensional PROMs—such as the Self-Assessed Disease Severity (SADS) scale, Dermatology Life Quality Index (DLQI), 5D-Itch Scale, Itch Severity Scale (ISS), and Skindex-10—provide broader insights into the psychological and social burden of pruritus. The DLQI is one of the most widely used instruments across dermatological conditions, evaluating the impact of itch across six domains of daily life.^30,31 While it is easily understood by clinicians across specialties and has strong psychometric properties, it can be time-consuming to administer. Therefore, its use is more appropriate for research settings rather than routine clinical practice.

Figure 2.

An individualised CKD-aP diagnostic algorithm.

Section 3: Stepwise management algorithm for CKD-associated pruritus (CKD-aP)

This section outlines a comprehensive, stepwise approach to the treatment of CKD-aP, integrating both non-pharmacological and pharmacological options, guided by symptom severity and patient-specific factors, as demonstrated in Figure 3.

Figure 3.

An individualised CKD-aP management algorithm.

A wide range of therapeutic interventions targeting multifactorial pathophysiology have been investigated for CKD-aP, while many treatments remain off-label. Current treatment follows a stepwise approach, starting with topical emollients and antihistamine for mild cases, followed by systemic agents such as gabapentinoids or κ-opioid receptor agonists (e.g., difelikefalin) for moderate-severe pruritic cases, and progressing to adjunctive options such as phototherapy, or acupuncture for treatment-resistant cases. Notably, CKD-aP may be partly reversible, as successful renal transplantation has been shown to significantly reduce its prevalence.³² Authors have synthesized a summary table (Table 1) depicting the recommended therapeutic agents for management of CKD-aP according to grade of recommendation/level of evidence which is based on GRADE working group.

Step 1: Optimise dialysis and correct CKD-MBD abnormalities

Dialysis and CKD-MBD optimization

Initial management aims at identifying and addressing reversible contributors to pruritus. Optimising dialysis adequacy—typically targeting a Kt/V of ≥1.2–1.4—is essential, as inadequate clearance of middle molecules may exacerbate symptoms. Similarly, correction of mineral and bone disorder (CKD-MBD) through dietary measures, phosphate binders, vitamin D analogues, or calcimimetics should be ensured. Although this is considered foundational, the relationship between CKD-MBD parameters (such as serum phosphate, calcium, and parathyroid hormone) and pruritus severity remains inconsistent. For instance, Fishbane et al. found no significant correlation between serum phosphate levels and pruritus intensity in hemodialysis patients, and no definitive threshold values have been established. Nonetheless, addressing CKD-MBD abnormalities remains a prudent and necessary first step.³³

Step 2: First-line symptom relief – Emollients and antihistamines

Topical and oral agents are employed early to address xerosis and relieve mild symptoms.

Emollients

Topical emollients help relieve itching associated with xerosis, which is common in CKD patients due to impaired skin barrier function. Preparations containing urea, glycerol, or paraffin are preferred for their hydrating properties.^2,14 Patients should be counselled to use a minimum of 200 g per week for adequate effect.³⁴

Topical alternatives

In cases of refractory xerosis or localized itch, topical agents such as capsaicin, pramoxine, or tacrolimus may be considered. These have shown benefit in reducing pruritus intensity in small studies and case series, particularly when conventional emollients are insufficient.^4,35

Antihistamines

Oral antihistamines are generally ineffective for CKD-associated pruritus (CKD-aP), as histamine is not a primary mediator in its pathophysiology.^3,36 The choice on first-generation (e.g., hydroxyzine, diphenhydramine) or 2nd generation (e.g., cetirizine, loratadine, fexofenadine) antihistamines may be considered in selected cases. Overall, their use requires caution, especially in elderly patients, due to the increased risk of cognitive impairment, daytime somnolence, reduced alertness, and falls.^36,37 They are still commonly prescribed, as CKD-aP often overlaps with eczema.

Step 3: Moderate to severe pruritus – Gabapentinoids, difelikefalin

Patients with persistent symptoms require escalation to systemic therapies, including novel agents.

Gabapentinoids

Gabapentin and pregabalin have demonstrated strong efficacy in reducing pruritus intensity, supported by multiple double-blind, placebo-controlled trials and meta-analyses.³⁸ Their mechanism involves modulation of voltage-gated calcium channels, which reduces neural hypersensitivity and pruritic signaling. Both agents exhibit comparable efficacy, with the choice largely dependent on physician preference and drug availability.³⁹ As these medications are renally excreted, dose adjustments are essential in patients with kidney failure to avoid oversedation (Table 2). For hemodialysis patient, the recommended dosage is 100–300 mg of gabapentin or 25–75 mg of pregabalin, administered thrice weekly after dialysis.³⁹ Although both drugs are dialyzable, post-dialysis supplementation is generally unnecessary. Despite providing rapid symptom relief in up to 85% of patients,⁴⁰ their widespread use is often limited by common adverse effects, including dizziness, somnolence, and fatigue.

Table 2.

Gabapentinoid dosing and titration in CKD-aP (by CKD stage).

CKD stage	eGFR (mL/min/1.73 m²)	Gabapentin dose	Pregabalin dose	Clinical notes
CKD 1–2	≥60	300–900 mg/day in 2–3 divided doses	75–150 mg/day in 2 divided doses	Use standard dosing. Monitor for side effects in elderly.
CKD 3 (moderate)	30–59	200–700 mg/day in 1–2 divided doses	50–75 mg/day in 1–2 divided doses	Start low; titrate slowly to avoid oversedation.
CKD 4 (severe)	15–29	100–300 mg/day, once daily or every other day	25–50 mg/day, once daily or every other day	Risk of accumulation. Use caution in older or frail patients.
CKD 5 (not on dialysis)	<15	100–300 mg every 2–3 days	25–50 mg every 2–3 days	Avoid regular dosing. Increased risk of neurotoxicity.
CKD 5 (HD)	On hemodialysis	100 mg post-HD (3x/week)	25 mg post-HD (3x/week)	Give only after HD. Titrate by 25–100 mg/week as tolerated. Max: Gabapentin 300 mg, pregabalin 75 mg.
CKD 5 (PD)	On peritoneal dialysis	100 mg daily or every other day	25 mg daily	Less removed by PD. Titrate slowly. Monitor closely for CNS effects.

Difelikefalin

Difelikefalin is a selective κ-opioid receptor (KOR) agonist that provides targeted relief of pruritus without the adverse effects typically associated with mu-opioid receptor (MOR) stimulation as shown in Figure 4. It is the first FDA (United States), EMA (European Union) and HSA (Health Sciences Authority) of Singapore-approved treatment for moderate-to-severe CKD-associated pruritus (CKD-aP).⁴¹ Its efficacy and safety were demonstrated in two pivotal phase 3 randomized controlled trials—KALM-1 and KALM-2. In KALM-1, 51.9% of hemodialysis patients treated with difelikefalin achieved a clinically meaningful reduction of ≥3 points on the Worst Itch Numerical Rating Scale (WI-NRS), compared to 30.9% in the placebo group. These results were consistent with findings from KALM-2, further validating the therapeutic benefit. Patients also reported significant improvements in itch-related quality of life, including better sleep, emotional well-being, and social engagement, as assessed by instruments such as the 5-D Itch Scale and Skindex-10.^41–43 Difelikefalin was generally well-tolerated, with common adverse events including diarrhea, dizziness, somnolence, and mental status changes, most of which were mild to moderate in severity. There is data supporting tolerability for up to 64 weeks also.^5,41 These findings support difelikefalin’s role as a safe and effective treatment option for hemodialysis patients suffering from moderate-to-severe CKD-aP. This treatment can only be prescribed by a dermatologist/nephrologist and administered during haemodialysis.

Figure 4.

Mechanism of action of difelikefalin.

Nalfurafine

Nalfurafine is a centrally acting selective κ-opioid receptor agonist approved in Japan in 2009 for the treatment of CKD-aP. Phase 3 RCTs in Japanese dialysis patients demonstrated significant reductions in itch severity with 2.5–5 µg/day nalfurafine compared to placebo.⁴⁴ However, its availability remains limited (only Japan and Korea), and its use is associated with central nervous system side effects, including insomnia and hallucinations at higher doses. Thus, while it offers a convenient oral option, its use remains limited to this specific hemodialysis patient group and geographic region.

Step 4: Refractory cases – Phototherapy and specialist involvement

Phototherapy

Narrowband ultraviolet B (NB-UVB) therapy has shown efficacy in reducing pruritus severity by modulating immune pathways and lowering pro-inflammatory cytokine levels.^31,32 However, its use may be limited by accessibility, cost, and concerns over long-term skin cancer risk, especially in immunosuppressed patients. This treatment can only be prescribed by a dermatologist. Patients must also be physically able to tolerate short-duration sessions (1–3 times per week).

Other non-pharmacological options

Acupuncture, transcutaneous electrical nerve stimulation (TENS), and omega-3 fatty acid supplementation—may be considered in refractory cases. Although some patients report benefit, the supporting evidence remains limited and further research is needed.^4,11

Other pharmacologic adjuncts

Serotonin (5-HT₃) antagonist (ondansetron)

Serotonin (5-HT3) receptor antagonists such as ondansetron have been studied for their antipruritic effects due to serotonin’s role in pruritus signaling. While small studies have shown modest improvement in CKD-aP symptoms, the evidence remains limited and inconsistent.⁴⁵ Given their favorable safety profile, serotonin antagonists may be considered in select cases, although they are not routinely recommended.

Selective serotonin reuptake inhibitors (SSRIs)

SSRIs, including paroxetine and sertraline, have been explored for pruritus management due to their modulatory effects on central neurotransmitters involved in itch perception. Some reports suggest a benefit,⁴⁶ particularly in patients with concurrent depression or anxiety, but clinical trial data are sparse. SSRIs may be useful as adjuncts in CKD-aP cases with a strong psychogenic component, rather than as primary therapy.

Naltrexone/Naloxone

Both are mu-opioid receptor antagonists that have been investigated for pruritus management based on the theory that mu-receptor overstimulation contributes to itch. Some small studies have reported symptomatic improvement in CKD-aP, but the results are inconsistent. A randomized crossover study (n = 23) showed no statistically significant benefit compared to placebo; moreover, side effects were common.⁴⁷ They are not widely used due to the limited efficacy and potential side effects, including nausea and hepatotoxicity.

Nalbuphine

Nalbuphine is a mixed mu-opioid receptor antagonist and κ-opioid receptor agonist, offering a dual mechanism that may alleviate pruritus. Early phase clinical studies in dialysis patients have shown promising results in itch reduction with an acceptable safety profile.⁴⁸ However, more robust, large-scale trials are needed to confirm its role in CKD-aP management.

Discussion

Chronic kidney disease-associated pruritus (CKD-aP) is a prevalent and distressing symptom, especially among patients undergoing maintenance on dialysis. It significantly impairs health-related quality of life and has been associated with poor sleep, depression, and increased mortality. An effective approach to CKD-aP management requires a multidisciplinary strategy that includes nephrologists, dermatologists, dialysis nurses, and active patient involvement.

Traditionally, the management of CKD-aP has centred on nephrology-led strategies, particularly the optimisation of dialysis adequacy and correction of biochemical derangements. While these remain foundational, they are frequently inadequate to address moderate-to-severe or refractory pruritus. Dermatologists can provide critical expertise in the evaluation and management of chronic itch, offering therapies such as topical corticosteroids, emollients, and phototherapy, which complement nephrologist-led treatment approaches.

Pharmacological management is a cornerstone of CKD-aP care. Among current options, gabapentinoids (gabapentin and pregabalin) are the most extensively studied, consistently demonstrating efficacy in symptom relief. In recent years, κ-opioid receptor agonists, particularly difelikefalin, have emerged as effective alternatives. Although no head-to-head trials have been conducted between gabapentinoids and difelikefalin, the latter’s approval in the United States and Europe supports its use in patients with treatment-resistant symptoms. Drug selection should be guided by shared decision-making and tailored to patient-specific factors, including comorbidities, tolerability, and functional status. For example, difelikefalin may be preferred in elderly dialysis patients who are at increased risk of sedation from gabapentinoids.

A proposed CKD-aP treatment algorithm (Figure 4) includes both first-line agents and escalation pathways. For patients with refractory pruritus, early referral to specialised pruritus clinics is recommended. Such centres can facilitate access to advanced treatments, including phototherapy, systemic immunomodulators, or emerging biologics.

Despite promising clinical trial results and regulatory approvals, access to newer therapies such as difelikefalin remains limited in Singapore. Key barriers include its absence from public hospital formularies, high cost, and a lack of local protocols or standard operating procedures for administration. In international practice, trained dialysis nurses routinely administer difelikefalin post-dialysis without physician supervision. However, Singapore’s initial adoption may necessitate physician-administered first doses and additional nursing protocol development. With structured training and established SOPs, nurse-led administration is both safe and feasible, and may facilitate broader uptake in the local setting.

Affordability poses a further challenge. Difelikefalin is estimated to cost approximately SGD 4200 per year in some international markets. Without health technology assessment endorsement or inclusion in subsidy schemes such as MediSave, patient access in Singapore is likely to be constrained by financial limitations. Even in countries with strong public funding mechanisms, such as Canada, similar cost-related access issues have been reported. Moreover, awareness of CKD-aP and its newer therapies among nephrologists and dialysis providers in Singapore remains variable. In the absence of national clinical guidelines or consensus statements, many patients may continue to receive off-label treatments with limited effectiveness and tolerability.

Globally, cost-effectiveness analyses have supported the use of difelikefalin. The United Kingdom’s National Institute for Health and Care Excellence (NICE) approved difelikefalin based on a favourable incremental cost-effectiveness ratio (ICER) of approximately GBP 22,000 per quality-adjusted life year (QALY), within the accepted cost-effectiveness threshold.⁴⁹ Similar endorsements have been reported in Australia and selected European nations. Another κ-opioid receptor agonist, nalfurafine, which is approved in Japan and South Korea, has also demonstrated efficacy and may warrant further consideration for wider international use.¹⁹

In Singapore, improving CKD-aP management will require several coordinated efforts. These include enhancing clinician education on symptom recognition, integrating patient-reported outcome measures into routine care, strengthening interdisciplinary collaboration with dermatologists, and expanding access to novel therapies. Policymakers should consider evaluating difelikefalin through health technology assessment frameworks to support its subsidised availability. Patient education on the burden and treatment options for pruritus should also be prioritised to facilitate informed decision-making and better health outcomes.

Future research priorities in the local context should include epidemiological studies to assess CKD-aP prevalence, the integration of PROMs in dialysis settings, and evaluation of prescription trends and treatment satisfaction among Singapore’s dialysis population. Generating such evidence will be crucial in informing clinical guidelines, healthcare resource planning, and equitable access to effective pruritus therapies.

Conclusion

CKD-aP is a prevalent, underrecognized, and debilitating condition. A stepwise, algorithmic approach—including screening, exclusion, and PROM-based severity assessment—can enhance physician awareness and support personalized management plans. Interdisciplinary collaboration in optimizing patient-centered care via a combination of pharmacological and non-pharmacological interventions remains the cornerstone of CKD-aP management. Future research should focus on refining treatment guidelines such as head-to-head comparisons of existing treatments, exploring alternative administration routes, such as subcutaneous or oral κ-receptor agonists, could expand treatment options for patients on peritoneal dialysis, kidney transplant recipients, and those opting for conservative management.

Footnotes

Acknowledgements

We would like to thank Vifor Pharma for the technical assistance with the diagrams.

ORCID iDs

Sye Nee Tan

Boon Cheok Lai

Derrick Chen Wee Aw

Author contributions

TSN and DA researched literature and conceived the study. TSN and LBC was involved in protocol development and data analysis. LBC wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.*

References

Yosipovitch

Skayem

Saint Aroman

, et al. International study on prevalence of itch: examining the role of itch as a major global public health problem. Br J Dermatol 2024; 191(5): 713–718.

Grundmann

Ständer

. Chronic pruritus: clinics and treatment. Ann Dermatol 2011; 23(1): 1. https://doi.org/10.5021/ad.2011.23.1.1

Davies

. Nursing care and management of patients with pruritus. Nurs Stand 2007; 21(41): 51–57. https://doi.org/10.7748/ns2007.06.21.41.51.c4633

Rayner

Larkina

Wang

, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017; 12(12): 2000–2007. https://doi.org/10.2215/CJN.03280317

Fishbane

Wen

Munera

, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in haemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med 2022; 4: 100513. https://doi.org/10.1016/j.xkme.2022.100513

Jha

Garcia-Garcia

Iseki

, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382(9888): 260–272. https://doi.org/10.1016/s0140-6736(13)60687-x

Chang

Chung

Hsieh

, et al. Evaluation of the therapeutic effects of protocatechuic aldehyde in diabetic nephropathy. Toxins 2021; 13(8): 560. https://doi.org/10.3390/toxins13080560

Sang

Yang

, et al. Prevalence of chronic kidney disease-associated pruritis among adult dialysis patients: a meta-analysis of cross-sectional studies. Medicine. 2018; 97(21): 4–6.

SONG Executive Committee . Standardised outcomes in nephrology initiative. Available at. https://songinitiative.org/, 16 November 2021, date last accessed.

10.

Edith

Sue

Gill

, et al. The relationship between chronic kidney disease–associated pruritus and health-related quality of life: a systematic review. Clin Kidney J 2021; 1(0): 1–16.

11.

Shirazian

Aina

Park

, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovascular Dis 2017; 10: 11–26. https://doi.org/10.2147/IJNRD.S108045

12.

Pisoni

Wikstrom

Elder

, et al. Pruritus in haemodialysis patients: international results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant 2006; 21(12): 3495–3505. https://doi.org/10.1093/ndt/gfl461

13.

Titapiccolo

Lonati

Goethel-Paal

, et al. Chronic kidney disease-associated pruritus (CKD-aP) is associated with worse quality of life and increased healthcare utilization among dialysis patients. Qual Life Res 2023; 32(10): 2939–2950. https://doi.org/10.1007/s11136-023-03438-6

14.

Swarna

Aziz

Zubair

, et al. Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus 2019; 11(7): e5240. https://doi.org/10.7759/cureus.5256

15.

Peng

. Uremic pruritus: pathophysiology, clinical presentation, and treatments. Kidney Res Clin Pract 2022; 42(1): 39–52. https://doi.org/10.23876/j.krcp.21.189

16.

Chen

, et al. Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study. PLoS One 2013; 8(8): e71404. https://doi.org/10.1371/journal.pone.0071404

17.

Verduzco

Shirazian

. Chronic kidney disease-associated pruritus: new insights into diagnosis, pathogenesis and management. Kidney Int Rep 2020; 5(9): 1387–1402. https://doi.org/10.1016/j.ekir.2020.04.027

18.

Ständer

Steinhoff

. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11(1): 12–24. https://doi.org/10.1034/j.1600-0625.2002.110102.x

19.

Albert-Vartanian

Boyd

Hall

, et al.

Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential?

J Clin Pharm Therapeut 2016; 41(4): 371–382. https://doi.org/10.1111/jcpt.12404

20.

Wieczorek

Krajewski

Kozioł-Gałczyńska

, et al. Opioid receptors expression in the skin of haemodialysis patients suffering from uraemic pruritus. J Eur Acad Dermatol Venereol 2020; 34(10): 2368–2372. https://doi.org/10.1111/jdv.16360

21.

Makar

Smyth

Brennan

. Chronic kidney disease-associated pruritus: a review. Kidney Blood Press Res 2021; 46: 1–11. https://doi.org/10.1159/000518391

22.

Manenti

Leuci

. Do you feel itchy? A guide towards diagnosis and measurement of chronic kidney disease-associated pruritus in dialysis patients. Clin Kidney J 2021; 14: i8–i15. https://doi.org/10.1093/ckj/sfab143

23.

Lipman

Paramasivam

Yosipovitch

, et al. Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches. Clin Kidney J 2021; 14: i16–i22. https://doi.org/10.1093/ckj/sfab167

24.

Sukul

Karaboyas

Csomor

, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Med 2021; 3(1): 42–53.e1. https://doi.org/10.1016/j.xkme.2020.08.011

25.

Satoh

Yokozeki

Murota

, et al. 2020 guidelines for the diagnosis and treatment of cutaneous pruritus. J Dermatol 2021; 48(9): e399–e413. https://doi.org/10.1111/1346-8138.16066

26.

Esteve-Simó

Perez-Morales

Buades-Fuster

, et al. Chronic kidney disease-associated pruritus and quality of life: learning from our patients. J Clin Med 2023; 12(13): 4505. https://doi.org/10.3390/jcm12134505

27.

Elke

Uwe

Jörg

, et al. Questionnaires to assess chronic itch: a consensus paper of the special interest group of the international forum on the study of itch. Acta Derm Venereol 2012; 92: 493–496.

28.

Lopes

Karaboyas

Sukul

, et al. Utility of a single itch-related question and the Skindex-10 questionnaire for assessing pruritus and predicting health-related quality of life in patients receiving hemodialysis. Kidney Med 2022; 4(6): 100476. https://doi.org/10.1016/j.xkme.2022.100476

29.

Basra

Fenech

Gatt

, et al. The dermatology life quality index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997–1035. https://doi.org/10.1111/j.1365-2133.2008.08832.x

30.

Vyas

Johns

Ali

, et al. A systematic review of 457 randomised controlled trials using the dermatology life quality index: experience in 68 diseases and 42 countries. Br J Dermatol 2024; 190(3): 315–339. https://doi.org/10.1093/bjd/ljad079

31.

Mettang

. Uremic itch management. In: Szepietowski

Weisshaar

(eds). Itch: management in clinical practice. Karger, 2016, pp. 133–141.

32.

Afshar

Rebollo-Mesa

Murphy

, et al. Symptom burden and associated factors in renal transplant patients in the U.K. J Pain Symptom Manag 2012; 44(2): 229–238. https://doi.org/10.1016/j.jpainsymman.2011.08.005

33.

Fishbane

Block

Evenepoel

, et al. Pruritus severity and serum phosphate in CKD: a post hoc analysis of difelikefalin studies. Kidney 360 2024; 5(9): 1270–1280. https://doi.org/10.34067/kid.0000000000000520

34.

Rubel

Thirumoorthy

Soebaryo

, et al. Consensus guidelines for the management of atopic dermatitis: an Asia–Pacific perspective. J Dermatol 2013; 40: 1–12. https://doi.org/10.1111/1346-8138.12065

35.

Ständer

Siepmann

Herrgott

, et al. Topical calcineurin inhibitors in the treatment of chronic pruritus. J Am Acad Dermatol 2006; 54(4): 669–678. https://doi.org/10.1016/j.jaad.2005.11.1104

36.

Greaves

. Antihistamines in dermatology. Skin Pharmacol Physiol 2005; 18(5): 220–229. https://doi.org/10.1159/000086667

37.

Church

Maurer

Simons

FER

, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy 2010; 65(4): 459–466. https://doi.org/10.1111/j.1398-9995.2009.02325.x

38.

Hercz

Jiang

Webster

. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev 2020; 12(12): CD011393. https://doi.org/10.1002/14651858.CD011393.pub2

39.

Solak

Biyik

Atalay

, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology 2012; 17(8): 710–717. https://doi.org/10.1111/j.1440-1797.2012.01655.x

40.

Rayner

Baharani

Smith

, et al. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin Pract 2012; 122(3–4): 75–79. https://doi.org/10.1159/000349943

41.

Topf

Wooldridge

McCafferty

, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. Kidney Med 2022; 4(8): 100512. https://doi.org/10.1016/j.xkme.2022.100512

42.

Fotheringham

Guest

Latus

, et al. Impact of difelikefalin on the health-related quality of life of haemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus: a single-arm intervention trial. Patient 2024; 17(2): 203–213. https://doi.org/10.1007/s40271-023-00668-1

43.

Weiner

Schaufler

McCafferty

, et al. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis. Nephrol Dial Transplant 2024; 39(7): 1125–1137. https://doi.org/10.1093/ndt/gfad245

44.

Kumagai

Mackay

, et al. Oral nalfurafine hydrochloride in haemodialysis patients with pruritus: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25(12): 4210–4216.

45.

Murphy

Reaich

Pai

, et al. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003; 148(2): 314–317. https://doi.org/10.1046/j.1365-2133.2003.05172.x

46.

Sanjuan‐Hernández

Ojeda

, et al. Sertraline for uraemic pruritus in haemodialysis patients: a retrospective case series. Nefrologia 2022; 42(3): 279–285.

47.

Pauli-Magnus

Mikus

Alscher

, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11(3): 514–519.

48.

Cheung

Wilmer

Flanigan

, et al. Oral nalbuphine extended release for treatment of hemodialysis-associated pruritus: a randomized, double-blind, placebo-controlled phase 2 trial. Kidney Int Rep 2021; 6(1): 202–212. https://doi.org/10.1016/j.ekir.2020.10.038

49.

Thokala

Hernandez Alava

, et al. Cost effectiveness of difelikefalin compared to standard care for treating chronic kidney disease-associated pruritus (CKD-aP) in people with kidney failure receiving haemodialysis. Pharmacoeconomics 2023; 41(4): 457–466. https://doi.org/10.1007/s40273-022-01237-4

CKD-aP in focus: A comprehensive guide from recognition to relief for local practice

Abstract

Introduction

Methods

Results

Conclusion

Keywords

Introduction

Methods

Results

Section 1: Pathophysiology of CKD-aP

Section 2: Initial assessment (e.g., WI-NRS, SADS, DLQI etc.)

Section 3: Stepwise management algorithm for CKD-associated pruritus (CKD-aP)

Step 1: Optimise dialysis and correct CKD-MBD abnormalities

Dialysis and CKD-MBD optimization

Step 2: First-line symptom relief – Emollients and antihistamines

Emollients

Topical alternatives

Antihistamines

Step 3: Moderate to severe pruritus – Gabapentinoids, difelikefalin

Gabapentinoids

Difelikefalin

Nalfurafine

Step 4: Refractory cases – Phototherapy and specialist involvement

Phototherapy

Other non-pharmacological options

Other pharmacologic adjuncts

Serotonin (5-HT3) antagonist (ondansetron)

Selective serotonin reuptake inhibitors (SSRIs)

Naltrexone/Naloxone

Nalbuphine

Discussion

Conclusion

Footnotes

Acknowledgements

ORCID iDs

Author contributions

Funding

Declaration of conflicting interests

Data Availability Statement

References

Serotonin (5-HT₃) antagonist (ondansetron)